Market Place
Sourcing Support
SciBase announces sale of Nevisense to NIH (US)
27 Sep 2024 //
PR NEWSWIRE
Darzalex Based Maintenance Shows Deep Responses In Multiple Myeloma
27 Sep 2024 //
PR NEWSWIRE
Krka`s Pomalidomide Receives Approval in Europe
24 Sep 2024 //
EMA
Legend Biotech Reports Positive OS Results From CARTITUDE-4 Trial
02 Jul 2024 //
GLOBENEWSWIRE
Apotex`sGeneric Pomalidomide Receives Approval in US
11 Jun 2024 //
FDA
Pomavid®; Our dedication to shaping hope
07 Jun 2024 //
PRESS RELEASE
Belantamab Mafodotin Combo Reduced Progression Risk By ~50% In R/R Myeloma
02 Jun 2024 //
BUSINESSWIRE
Teva Pharm Generic Pomalidomide Receives Approval in the U.S.
04 May 2022 //
FDA
Mylan`s Generic Pomalidomide Receives Approval in the U.S.
26 Jan 2022 //
FDA
Oncopeptides phase 3 OCEAN study published in the Lancet Haematology
12 Jan 2022 //
PRNEWSWIRE
Pharmascience`s Generic Bortezomib Receives Approval in the U.S.
13 Dec 2021 //
FDA
Dr. Reddy`s Generic Pomalidomide Receives Approval in the U.S.
06 Dec 2021 //
FDA
Dr. Reddy`s Lab`s Generic Pomalidomide Receives Tentative Approval In US
22 Apr 2021 //
FDA
Halozyme Announces Janssen Submission In US And EU Approval DARZALEX FASPRO™
12 Nov 2020 //
PRNEWSWIRE
Immunomodulatory drugs: temporary pregnancy guidance during (COVID-19)
21 May 2020 //
GOVUK
Bristol Myers’ Pomalyst Approved by FDA for Kaposi Sarcoma
18 May 2020 //
BLOOMB BERGLAW
US FDA approves BMY`s’s Pomalyst for AIDS-related & HIV-negative Kaposi sarcoma
17 May 2020 //
PHARMABIZ
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Pomalyst®
15 May 2020 //
BUSINESSWIRE
CHMP backs Sanofi’s myeloma drug Sarclisa
28 Mar 2020 //
PMLIVE
EAMS scientific opinion given to Aventis Pharma
13 Jan 2020 //
GOV
J&J darzalex-FDA approval in frontline multiple myeloma use as Sanofi rival
28 Sep 2019 //
ENDPTS
EC OKs expanded label for Bristol-Myers` Empliciti
27 Aug 2019 //
SEEKINGALPHA
EU Approves Empliciti (elotuzumab) Pomalidomide & Low-Dose Dexamethasone (EPd)
27 Aug 2019 //
BUSINESSWIRE
Celgene`s Revlimid, Pomalyst leap ahead on new triple-combo OKs
31 Jul 2019 //
FIERCE PHARMA
Celgene’s Otezla, heading for selloff, nabs niche inflammation market
23 Jul 2019 //
FIERCE PHARMA
FDA accepts BLA filing for Sanofi`s rival to J&J`s Darzalex
11 Jul 2019 //
FIERCE BIOTECH
Karyopharm’s Xpovio nabs myeloma nod despite checkered past. But 5th line?
08 Jul 2019 //
FIERCE PHARMA
FDA lifts hold on AbbVie, Roche`s Venclexta in myeloma
25 Jun 2019 //
FIERCE PHARMA
Sanofi`s anti-CD38 combo boosts responses
03 Jun 2019 //
FIERCE BIOTECH
Revlimid, Imnovid combos receive EU approval
17 May 2019 //
PHARMA TIMES
Four years after EU approval, NICE finally backs Revlimid
17 May 2019 //
ENDPTS
Celgene Receives European Commission Approvals for REVLIMID®& IMNOVID®
16 May 2019 //
BUSINESSWIRE
Celgene Corporation Announces POMALYST® Granted Breakthrough Therapy Designation
13 May 2019 //
BUSINESSWIRE
Pomalyst (Pomalidomide) : Celgene Corp. vs. Hetero Drugs
30 Jan 2019 //
PATENT LITIGATION
Pomalyst (Pomalidomide): Celgene Corporation vs. Mylan
24 Nov 2018 //
PATENT LITIGATION
US approves new use for BMS’ Empliciti
08 Nov 2018 //
PHARMA TIMES
Pomalyst (Pomalidomide) : Celgene Corp. vs. Breckenridge Pharma
19 Oct 2018 //
PATENT LITIGATION
Drug Prices Mostly Continue to Climb, Despite Trump`s Promises
09 Oct 2018 //
BIOSPACE
Pomalyst (Pomalidomide) : Celgene Corp. vs. Teva Pharmaceuticals
02 Oct 2018 //
PATENT LITIGATION
Pomalyst (Pomalidomide): Celgene vs. Hetero Drugs Ltd.
21 Sep 2018 //
PATENT LITIGATION
EMA Validates Bristol-Myers’ Application for Empliciti (elotuzumab)+Pomalidomide
18 Sep 2018 //
BUSINESSWIRE
FDA Accepts for Priority Review BMS’ Empliciti (elotuzumab) Plus Pomalidomide
23 Aug 2018 //
BUSINESSWIRE
6 Reasons Celgene Remains The Best Valued Large-Cap Pharma Stock
02 Aug 2018 //
SEEKING ALPHA
Celgene, Roche and Novo increased prices on some top sellers
13 Jul 2018 //
FIERCE PHARMA
Data show Imnovid-based triple therapy PFS benefit in blood cancer
05 Jul 2018 //
PHARMA TIMES
Celgene pledges to limit price hikes—or does it?
03 Jul 2018 //
FIERCE PHARMA
Pomalyst® (Pomalidomide Capsules) : Celgene Corporation v. Synthon
21 Jun 2018 //
PATENT LITIGATION
FDA tries to shame drugmakers over tactics that delay generics
18 May 2018 //
FIERCE PHARMA
Patient death forces FDA to hold study using Advaxis, AstraZeneca
12 Mar 2018 //
ENDPTS
After months of searching, Immunomedics lines up Celgene vet Pehl as its new CEO
11 Nov 2017 //
FIERCE BIOTECH
Celgene takes aggressive price hikes on Revlimid, Pomalyst
24 Oct 2017 //
FIERCE PHARMA
FDA adds two Roche studies to its growing list of partial clinical holds
15 Sep 2017 //
ENDPTS
FDA sidelines Keytruda myeloma studies after trial deaths
07 Jul 2017 //
FIERCE PHARMA
FDA Suspends Certain Clinical Trials of Merck’s Keytruda
05 Jul 2017 //
CETUSNEWS
US FDA approves Darzalex in combo with pomalidomide & dexamethasone for patients
19 Jun 2017 //
PHARMABIZ
FDA Nod For Ipsen, XNCR On Watch, Results MAGNIFY CELG`s R2 Regimen
18 Jun 2017 //
NASDAQ
Pomalyst® (Pomalidomide ): Celgene Corporation V. Par Pharmaceutical & Teva
04 May 2017 //
PATENT LITIGATION
Celgene Notified of ANDA Filing for POMALYST®
04 Apr 2017 //
BUSINESSWIRE
